Evidence map›Paper›PMID 36243305›Full record

ArticleTransfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine2023

Blood-Type-A is a COVID-19 infection and hospitalization risk in a Turkish cohort.

Meryem Cetin, Sirin Cetin, Ayse Ulgen, Wentian Li

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Meryem CetinDepartment of Medical Microbiology, Faculty of Medicine, Amasya University, Amasya, Turkey.
Sirin CetinDepartment of Biostatistics, Amasya University, Amasya, Turkey.
Ayse UlgenDepartment of Biostatistics, Faculty of Medicine, Girne American University, 99320 Karmi, Cyprus; Department of Mathematics, School of Science and Technology, Nottingham Trent University, Nottingham NG11 8NF, UK. Electronic address: ayshe.ulgen@global.t-bird.edu.
Wentian LiThe Robert S. Boas Center for Genomics and Human Genetics, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA. Electronic address: wtli2012@gmail.com.
Amasya Üniversitesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We have shown in an ethnically homogenous Turkey cohort with more than six thousand cases and 25 thousand controls that ABO blood types that contain anti-A antibody (O and B) are protective against COVID-19 infection and hospitalization, whereas those without the anti-A antibody (A and AB) are risks. The A + AB frequency increases from 54.7 % in uninfected controls to 57.6 % in COVID-19 outpatients, and to 62.5 % in COVID-19 inpatients. The odds-ratio (OR) for lacking of anti-A antibody risk for infection is 1.16 (95 % confidence interval (CI) 1.1-1.22, and Fisher test p-value 1.8 × 10

Indexed as

COVID-19ABO Blood-Group SystemAntibodiesBlood Grouping and CrossmatchingHospitalizationHumansTurkeyABO Blood-Group SystemAntibodiesABO blood groupAnti-A antibodyCOVID-19Logistic regression

Identifiers

PMID36243305
PMCPMC9557134
OpenAlexW4304957607

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.